PMG
TEVA icon

Private Management Group’s Teva Pharmaceuticals TEVA Stock Holding History

Private Management Group’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$21.4M Sell
710,398
-178,797
-20% -$5.75M 0.62% 71
2025
Q4 		$27.8M Sell
889,195
-303,794
-25% -$7.48M 0.81% 50
2025
Q3 		$24.1M Sell
1,192,989
-162,630
-12% -$2.86M 0.72% 59
2025
Q2 		$22.7M Sell
1,355,619
-5,804
-0.4% -$93.7K 0.74% 59
2025
Q1 		$20.9M Buy
1,361,423
+179,758
+15% +$3.21M 0.75% 61
2024
Q4 		$26M Sell
1,181,665
-92,332
-7% -$1.68M 0.94% 40
2024
Q3 		$23M Sell
1,273,997
-101,434
-7% -$1.78M 0.81% 52
2024
Q2 		$22.4M Sell
1,375,431
-92,921
-6% -$1.43M 0.86% 47
2024
Q1 		$20.7M Sell
1,468,352
-49,086
-3% -$619K 0.78% 55
2023
Q4 		$15.8M Sell
1,517,438
-98,730
-6% -$922K 0.61% 74
2023
Q3 		$16.5M Sell
1,616,168
-47,641
-3% -$444K 0.68% 63
2023
Q2 		$12.5M Buy
1,663,809
+378,600
+29% +$3.07M 0.53% 81
2023
Q1 		$11.4M Sell
1,285,209
-9,547
-0.7% -$94.4K 0.51% 77
2022
Q4 		$11.8M Sell
1,294,756
-821,603
-39% -$7.17M 0.52% 75
2022
Q3 		$17.1M Sell
2,116,359
-98,442
-4% -$870K 0.8% 57
2022
Q2 		$16.7M Buy
2,214,801
+9,272
+0.4% +$80.8K 0.73% 61
2022
Q1 		$20.7M Buy
2,205,529
+105,115
+5% +$877K 0.84% 58
2021
Q4 		$16.8M Sell
2,100,414
-89,990
-4% -$812K 0.67% 62
2021
Q3 		$21.3M Buy
2,190,404
+80,842
+4% +$757K 0.89% 53
2021
Q2 		$20.9M Buy
2,109,562
+177,052
+9% +$1.87M 0.92% 56
2021
Q1 		$22.3M Buy
1,932,510
+811,163
+72% +$9.3M 1.02% 48
2020
Q4 		$10.8M Buy
1,121,347
+128,071
+13% +$1.23M 0.55% 71
2020
Q3 		$8.95M Buy
993,276
+36,189
+4% +$383K 0.58% 67
2020
Q2 		$11.8M Buy
957,087
+20,597
+2% +$233K 0.82% 51
2020
Q1 		$8.41M Sell
936,490
-29,910
-3% -$306K 0.69% 61
2019
Q4 		$9.47M Sell
966,400
-200,597
-17% -$1.79M 0.47% 79
2019
Q3 		$8.03M Buy
1,166,997
+15,668
+1% +$120K 0.43% 82
2019
Q2 		$10.6M Buy
1,151,329
+63,987
+6% +$772K 0.55% 72
2019
Q1 		$17.1M Sell
1,087,342
-383
-0% -$6.75K 0.85% 54
2018
Q4 		$16.8M Buy
1,087,725
+157,355
+17% +$3.23M 0.92% 50
2018
Q3 		$20M Buy
930,370
+10,837
+1% +$252K 0.94% 45
2018
Q2 		$22.4M Buy
919,533
+28,577
+3% +$583K 1.1% 38
2018
Q1 		$15.2M Sell
890,956
-8,225
-0.9% -$161K 0.81% 52
2017
Q4 		$17M Sell
899,181
-100,289
-10% -$1.51M 0.88% 49
2017
Q3 		$17.6M Buy
999,470
+256,269
+34% +$5.77M 0.93% 45
2017
Q2 		$24.7M Buy
743,201
+103,573
+16% +$3.21M 1.35% 23
2017
Q1 		$20.5M Buy
+639,628
New +$21.8M 1.16% 33

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Private Management Group's TEVA Position: Q1 2026 in Review

Private Management Group reduced its Teva Pharmaceuticals (TEVA) stake by 20% in Q1 2026, selling an estimated $5.75M and leaving 710,398 shares worth $21.4M. The position accounts for 0.62% of the portfolio, ranked #71.

Private Management Group first reported a position in TEVA in Q1 2017 and has held it in 37 quarters since. The position peaked at $27.8M in Q4 2025. 651 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

  • Private Management Group held 710,398 shares of Teva Pharmaceuticals worth $21.4M as of Q1 2026.
  • Private Management Group sold 178,797 Teva Pharmaceuticals shares in Q1 2026, an estimated $5.75M.
  • Teva Pharmaceuticals made up 0.62% of Private Management Group's portfolio in Q1 2026, its #71 holding.
  • Private Management Group first reported a position in Teva Pharmaceuticals in Q1 2017 and has held it in 37 quarters since.
  • Private Management Group's Teva Pharmaceuticals position peaked at $27.8M in Q4 2025.
  • 651 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Private Management Group's 13F filing for Q1 2026, filed 8 May 2026.